TLDR
- Cathie Wood’s ARK Invest purchased 781,519 Joby Aviation shares valued at $10.4 million following a 16.7% stock crash on January 29, 2026
- Joby Aviation’s stock decline came after announcing plans to raise $1 billion through common stock and convertible senior notes
- ARK sold 31,668 Teradyne shares for $7.9 million as the stock hit $253.61 following a MultiLane joint venture announcement
- The firm purchased 127,184 CRISPR Therapeutics shares for $6.8 million, maintaining its accumulation strategy in gene-editing technology
- ARK reduced stakes in Veracyte and Illumina while making minor trades in Beam Therapeutics and Kratos Defense
ARK Invest executed major portfolio changes on January 29, 2026, with electric aviation and biotech stocks taking center stage. The firm’s daily trading report revealed strategic positioning across multiple sectors.
The largest move involved Joby Aviation, where ARK acquired 781,519 shares worth $10.4 million. The purchase was distributed between ARK Autonomous Technology & Robotics ETF and ARK Space Exploration & Innovation ETF.
Joby Aviation experienced a 16.7% stock decline during Thursday’s session. The drop occurred after the company revealed plans for a substantial capital raise. The air taxi manufacturer aims to secure $1 billion through a combined offering of common stock and convertible senior notes due in 2032.
Investors reacted to concerns about equity dilution from the new share issuance. ARK capitalized on the sell-off to expand its position in the emerging flying taxi market.
Gene-Editing Stake Increases
ARK Invest continued building its biotech portfolio with a CRISPR Therapeutics purchase. The firm bought 127,184 shares totaling $6.8 million across ARKK and ARKG ETFs.
This transaction follows a pattern of steady accumulation in CRISPR stock. ARK has been adding shares over multiple consecutive trading days. The gene-editing company’s shares dipped slightly during Thursday’s market session.
Semiconductor Holdings Trimmed
ARK reduced its Teradyne exposure by selling 31,668 shares for $7.9 million. The transactions occurred through ARKQ and ARKX ETFs. Teradyne stock reached an intraday peak of $253.61 during trading.
The timing coincided with positive corporate developments. Teradyne and MultiLane announced the creation of MultiLane Test Products, a joint venture targeting AI data center testing needs.
MultiLane will transfer its test and measurement assets to the new company. The firm retains its interconnect products and data center testing divisions. Teradyne will hold majority ownership in the partnership.
The deal awaits regulatory clearance. Both companies anticipate closing the transaction in the first half of 2026. ARK has been systematically reducing its Teradyne position over recent days.
Portfolio Rebalancing Continues
ARK divested 31,463 Veracyte shares through ARKK ETF, generating proceeds of $1.2 million. The firm decreased its Illumina holdings by 35,897 shares across ARKK and ARKG ETFs. These sales continue ARK’s recent pattern of exiting positions in both healthcare companies.
Minor trades included purchasing 29,413 Beam Therapeutics shares. ARK sold 261 Kratos Defense and Security Solutions shares in a smaller adjustment. Analysts maintain “Moderate Buy” ratings on Teradyne and CRISPR Therapeutics, while Joby Aviation receives a “Hold” rating with potential 41% upside over the next twelve months.
